RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 State of the Art Treatment for Lung Cancer
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 32
OP 33
DO 10.1177/155989771306025
UL http://mdc.sagepub.com/content/13/6/32.abstract
AB Four to six cycles of platinum-based doublet chemotherapy remains the standard treatment protocol for most patients with advanced non-small cell lung cancer (NSCLC). Longer treatment does not appear to increase overall or progression-free survival and may lead to toxicity issues and reduced quality of life. This article discusses the current state of knowledge concerning treatment for NSCLC patients without a targetable (driver) mutation, the impact of oncogenic drivers on treatment of NSCLC, as well as the use of maintenance therapy for patients with cancer as a way to delay disease progression and improve survival.